Literature DB >> 26648621

Simeprevir.

.   

Abstract

Entities:  

Year:  2014        PMID： 26648621      PMCID： PMC4653988          DOI： 10.18773/austprescr.2015.026

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  7 in total

1.  Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.

Authors:  M P Manns; M W Fried; S Zeuzem; I M Jacobson; X Forns; F Poordad; M Peeters; M Fu; O Lenz; S Ouwerkerk-Mahadevan; W Jessner; J A Scott; R Kalmeijer; G De La Rosa; R Sinha; M Beumont-Mauviel
Journal:  J Viral Hepat       Date:  2014-11-03       Impact factor: 3.728

2.  Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.

Authors:  Xavier Forns; Eric Lawitz; Stefan Zeuzem; Ed Gane; Jean Pierre Bronowicki; Pietro Andreone; Andrzej Horban; Ashley Brown; Monika Peeters; Oliver Lenz; Sivi Ouwerkerk-Mahadevan; Jane Scott; Guy De La Rosa; Ronald Kalmeijer; Rekha Sinha; Maria Beumont-Mauviel
Journal:  Gastroenterology       Date:  2014-03-03       Impact factor: 22.682

3.  Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Michael Manns; Patrick Marcellin; Fred Poordad; Evaldo Stanislau Affonso de Araujo; Maria Buti; Yves Horsmans; Ewa Janczewska; Federico Villamil; Jane Scott; Monika Peeters; Oliver Lenz; Sivi Ouwerkerk-Mahadevan; Guy De La Rosa; Ronald Kalmeijer; Rekha Sinha; Maria Beumont-Mauviel
Journal:  Lancet       Date:  2014-06-04       Impact factor: 79.321

4.  Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Ira M Jacobson; Gregory J Dore; Graham R Foster; Michael W Fried; Monica Radu; Vladimir V Rafalsky; Larysa Moroz; Antonio Craxi; Monika Peeters; Oliver Lenz; Sivi Ouwerkerk-Mahadevan; Guy De La Rosa; Ronald Kalmeijer; Jane Scott; Rekha Sinha; Maria Beumont-Mauviel
Journal:  Lancet       Date:  2014-06-04       Impact factor: 79.321

5.  Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.

Authors:  Douglas Dieterich; Jürgen Kurt Rockstroh; Chloe Orkin; Félix Gutiérrez; Marina B Klein; Jacques Reynes; Umesh Shukla; Alan Jenkins; Oliver Lenz; Sivi Ouwerkerk-Mahadevan; Monika Peeters; Guy De La Rosa; Lotke Tambuyzer; Wolfgang Jessner
Journal:  Clin Infect Dis       Date:  2014-09-05       Impact factor: 9.079

6.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Authors:  Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

7.  Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.

Authors:  Stefan Zeuzem; Thomas Berg; Edward Gane; Peter Ferenci; Graham R Foster; Michael W Fried; Christophe Hezode; Gideon M Hirschfield; Ira Jacobson; Igor Nikitin; Paul J Pockros; Fred Poordad; Jane Scott; Oliver Lenz; Monika Peeters; Vanitha Sekar; Goedele De Smedt; Rekha Sinha; Maria Beumont-Mauviel
Journal:  Gastroenterology       Date:  2013-11-01       Impact factor: 22.682
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.